1,309 reports of this reaction
4.8% of all ATAZANAVIR reports
#2 most reported adverse reaction
DEPRESSION is the #2 most commonly reported adverse reaction for ATAZANAVIR, manufactured by E.R. Squibb & Sons, L.L.C.. There are 1,309 FDA adverse event reports linking ATAZANAVIR to DEPRESSION. This represents approximately 4.8% of all 27,247 adverse event reports for this drug.
Patients taking ATAZANAVIR who experience depression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEPRESSION is moderately reported among ATAZANAVIR users, representing a notable but not dominant share of adverse events.
In addition to depression, the following adverse reactions have been reported for ATAZANAVIR:
The following drugs have also been linked to depression in FDA adverse event reports:
DEPRESSION has been reported as an adverse event in 1,309 FDA reports for ATAZANAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEPRESSION accounts for approximately 4.8% of all adverse event reports for ATAZANAVIR, making it one of the most commonly reported side effect.
If you experience depression while taking ATAZANAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.